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model: 1): ﬁrst episode—FE; 2) low dependency state—LDS; 3) high dependency 
state—HDS; 4) Stable; 5) Well; and 6) Death. Patients’ movements between these 
disease states deﬁned 17 probability transitions to be estimated. The model was based 
on data from the RAMQ and Med-Echo databases, which were linked. All individuals 
aged 0–60 years with a new diagnosis of schizophrenia between 1998 to 2000 were 
ﬁrst identiﬁed by ICD-9 codes. Each individual was followed for a maximum of 8 
years. Using this data, Cox proportional hazard models for competing risks were used 
to estimate the 17 probabilities of transition. RESULTS: A total of 12,754 individuals 
were identiﬁed as newly diagnosed patients with schizophrenia. After the FE of 
schizophrenia, 69.8% of patients passed in LDS, 11.2% in HDS, 1% in death state 
and 18% in Well state. The mean transition probabilities after one year of follow-up 
were: FE to Well at 0.28 (oSD  0.10), FE to HDS at 0.11 (o0.05), FE to LDS at 0.60 
(o0.08) and respectively FE to Death at 0.01 (o0.01). The corresponding values were 
similar to those obtained from other published models (i.e. 0.24, 0.15, and 0.61 with 
a mortality rate of 0.008 per year). The results for the other 5 transition probabilities 
were similar to literature data. CONCLUSIONS: This model is the ﬁrst Canadian 
model incorporating transition probabilities adjusted for individual risk factors pro-
ﬁles using Canadian data. Future applications will include pricing and cost- 
effectiveness of new therapies for schizophrenia.
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OBJECTIVES: Evidence suggests depression rates are high among type-2 diabetic 
populations and untreated depression can complicate effective management of diabe-
tes. However, accurately characterizing depression in research study cohorts can be 
challenging. As part of the Health Related Quality of Life(HRQL) substudy in the 
Action to Control Cardiovascular Risk in Diabetes(ACCORD) trial, we collected data 
on depression from 2053 adult type-2 diabetics in North America. We use baseline 
data to evaluate the overlap between depression states and associations with selected 
demographic, lifestyle, and physical variables. METHODS: The 9-item depression 
scale from the Patient Health Questionnaire(PHQ-9) was used to assess current 
depression symptoms; history of depression was determined by participant self-report 
of prior physician diagnosis; and current use of antidepressant medications based on 
review of medications. Overlap between the three assessments was examined using 
cross-tabs, and associations with covariates were assessed using univariate logistic 
regression. RESULTS: Among the 1939 substudy participants with complete data, 
701 (36.2%) participants had at least one classiﬁcation of depression, including 537 
(27.7%) reporting either history (24.6%) or current anti-depressant use (13.9%) and 
378 (19.5%) a PHQ score higher than 9. Among the latter, 214 (56.6%) reported no 
history of physician-diagnosed depression or use of antidepressant medications. Par-
ticipants with younger age, female gender, larger BMI, larger waist circumference, 
higher cholesterol, or insulin use had signiﬁcantly (p  0.05) increased odds of all 
classiﬁcations of depression. Race/ethnicity, smoking status, HbA1c, serum creatinine, 
living alone, diet, alcohol use, blood pressure, amputations, QALYs, and other medi-
cation use were related to some, but not all deﬁnitions of depression. Prior CVD, 
duration of diabetes, education, GFR, LDL, HDL did not have signiﬁcant relationships 
with any deﬁnition. CONCLUSIONS: Characterization of depression in research set-
tings is complicated. In ACCORD, we ﬁnd different covariate relationships for deﬁni-
tions based on history versus current symptoms. These examinations may enhance our 
understanding of depression’s impact on disease management and cardiovascular 
risk.
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OBJETIVOS: Segundo o Instituto Nacional do Câncer (INCA, 2005), cerca de 50% 
dos diagnósticos de câncer de mama no Brasil se tratam de casos avançados da doença 
(estádio III e IV), resultando no máximo em 36% de taxa de sobrevida em 5 anos 
para estas mulheres (The Susan G. Komen Breast Câncer Foundation). Acredita-se 
que esta alta mortalidade poderia ser reduzida através da melhoria no acompanha-
mento e métodos de diagnóstico empregados com a população. Com isso, a Associa-
ção Hospitalar Moinhos de Vento associou-se com a Secretaria da Saúde Do Rio 
Grande do Sul no desenvolvimento de um estudo para medir o impacto de exames 
clínicos associados à mamograﬁa preventiva anual na população feminina acima dos 
40 anos da cidade de Porto Alegre. MÉTODOS: Foram acompanhadas 9,218 mul-
heres assintomáticas entre 40 e 69 anos de idade, provenientes de 18 unidades e Postos 
de Saúde da cidade de Porto Alegre. Para estas, foram realizados exames clínicos e 
mamograﬁa de rastreamento anual. Esta análise se refere aos primeiros quatro anos 
do projeto, e seus resultados foram comparados com dados epidemiológicos do INCA. 
RESULTADOS: Dentre o universo pesquisado, 50 mulheres foram diagnosticadas 
com câncer de mama. Comparando-se o estadiamento no diagnostico destas mulheres 
com os dados fornecidos pelo INCA para a região temos: estádio 0 (16% VS 6.7%), 
estádio I (38% VS 20.6%), estadio II (32% VS 45%), estádio III (10% VS 20%) e 
estádio IV (4% VS 7.7%). CONCLUSÕES: O estudo mostrou que o acompanha-
mento anual associado à mamograﬁa preventiva para as mulheres acima dos 40 anos 
aumentam sua possibilidade de diagnóstico precoce do câncer de mama, trazendo 
assim uma melhor perspectiva de sobrevida e cura. Assim, a adoção nacional deste 
protocolo poderia reduzir os altos níveis de mortalidade relacionados com esta neo-
plasia no Brasil.
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OBJECTIVOS: Los criterios de Beers (CB) permiten identiﬁcar prescripción de medi-
camentos potencialmente inapropiados (PMPI) según la condición de fragilidad del 
anciano. Determinar la tasa de PMPI en pacientes q65 años en la Unidad Geriátrica 
de Agudos (UGA) del Hospital Clínico de la Universidad de Chile. METODOLOGÍAS: 
Entre junio del 2006 y enero del 2009 se realizó un seguimiento prospectivo intensivo 
de los pacientes hospitalizados en la UGA, que cumplieran los criterios de inclusión 
(q65 años, ambos sexos, sin patología terminal), se registró la información desde ﬁchas 
clínicas, entrevistas y visitas médicas, la calidad de la prescripción fue evaluada con 
los CB y la mortalidad atribuible a co-morbilidades mediante el índice de Charlson. 
Los datos fueron analizados con STATA 10.0. RESULTADOS: De los 426 pacientes 
hospitalizados entre 2006 y 2009, 239 (56.1%) cumplieron los criterios de selección. 
La edad promedio fue 80.6 o 7.4 años y 66.9% (160) eran mujeres. La principal causa 
de ingreso fue delirium (28.9%). Se indicaron 2548 medicamentos, el número prome-
dio por paciente fue de 10.6 o 4.6 medicamentos. El 2.8% (72) fueron PMPI y el 
84.7% de ellas fue de severidad alta. El 24,7%(59) pacientes recibieron al menos 1 
PMPI. Los principales PMPI encontrados fueron clorfenamina (18.1%) y amiodarona 
(16.7%). El promedio de días de hospitalización y de medicamentos usados en paci-
entes con PMPI fue signiﬁcativamente superior a los sin PMPI, 12.0 o 9.6 y 8.9 o 7.0 
días, p  0.0046 y 13.2 o 5.2 y 9.8 o 4.1 medicamentos, p  0.0001, respectivamente. 
No se observaron diferencias signiﬁcativas entre los grupos con PMPI y sin PMPI para 
número de comorbilidades, índice de Charlson, edad, sexo. CONCLUSIONES: La 
asociación signiﬁcativa entre PMPI y el incremento de días de hospitalización y 
número de medicamentos usados, demuestra la necesidad de evaluar y monitorizar 
estrechamente las prescripciones a ancianos, para promover el uso adecuado de los 
medicamentos en este grupo etáreo.
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OBJECTIVES: When estimating expected occurrences of events in patient popula-
tions, background rates from published literature are often applied thereby creating 
comparative statistics such as the Standardized Incidence Ratio. However, in order to 
adequately estimate the occurrence of events the probabilities of the events have to be 
available according to the main risk factors for the event. Also the patient population 
needs to have the same granularity in order to marry the risk factor speciﬁc rates to 
the patient characteristics. Through the example of safety outcomes for glaucoma 
therapy, we describe an approach to create appropriate background occurrences 
for the outcomes of heart failure (HF), asthma/COPD exacerbation and death. 
METHODS: A cross section of glaucoma patients were identiﬁed on January 1, 2007 
from The Health Improvement Network “THIN”, a UK primary care database widely 
used for medical research. As well as age and sex, patients were categorized according 
to risk factors for HF (Hx HF, hypertension) and asthma/COPD (Hx asthma/COPD, 
smoking and diabetes). General population rates of these for the same categories 
events were calculated from the three million people registered with THIN on January 
1, 2006. These rates were assigned to each glaucoma patient and the expected number 
of events over one year for 10,000 patients was calculated. UK national statistics 
provided the death rates. RESULTS: The median age of the 31,535 glaucoma patients 
was 74 years and 46% were male. The prevalence of HF was 4%, asthma 13%, COPD 
6% and smoking 12%. For 10,000 patients we can expect 64 HF events, 139 asthma/
COPD exacerbations and 524 deaths each year. Due to different patient characteris-
tics, the expected occurrences were lower in timolol treated patients as opposed to 
latanoprost users. CONCLUSIONS: The use of databases provides more appropriate 
and granular background rates than from published rates. The approach can be used 
in risk-beneﬁt models.
